Publications by authors named "S E Rebuzzi"
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Cancer Immunol Immunother
January 2025
Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase inhibitors (TKIs), has radically changed the treatment landscape for metastatic RCC, showing varying efficacy across different prognostic groups based on the International Metastatic RCC Database Consortium (IMDC) criteria.
Materials And Methods: This retrospective multicenter study, part of the ARON-1 project, aimed to evaluate the outcomes of favorable-risk metastatic RCC patients treated with immune-based combinations or sunitinib.
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.
Clin Genitourin Cancer
November 2024
Article Synopsis
- The IMDC score is crucial for predicting outcomes and guiding treatment in patients with metastatic renal cell carcinoma (mRCC), especially when starting therapy with nivolumab.
- A multicenter study analyzed 492 mRCC patients to see how changes in IMDC categories affected their overall survival (OS) and progression-free survival (PFS) after starting nivolumab.
- Results indicated that patients maintaining or improving their IMDC category had better survival outcomes compared to those whose condition worsened, highlighting the importance of IMDC monitoring in mRCC treatment.
Article Synopsis
- The study evaluates the real-world effectiveness of the Pembrolizumab/Axitinib combination therapy for metastatic renal cell carcinoma (mRCC) in Italy, involving 170 patients treated between December 2020 and September 2023.
- Most participants had clear-cell histology (83%), and the treatment showed a median progression-free survival (PFS) of 19.2 months, with 84.6% achieving disease control.
- The study highlights key prognostic factors, including age and histology, that affect overall survival (OS) and establishes the combination's promise in clinical settings.
Article Synopsis
- - Enfortumab vedotin (EV) is effective for patients with advanced urothelial carcinoma who have previously received platinum chemotherapy and immune therapy, despite lacking research on those treated with avelumab maintenance.
- - A study of 182 patients showed a median overall survival of 12.7 months and a progression-free survival of 7.9 months, with 39% achieving a positive response to EV after avelumab treatment.
- - The study confirms EV's effectiveness, suggesting it can be a viable option for patients previously treated with avelumab, with manageable side effects like grade ≥ 3 neuropathy and skin rash occurring in a minority of cases.
To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab. A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs.
View Article and Find Full Text PDF